bacteremia

Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent

We read with interest the paper by Giacobbe et al. estimating a cumulative risk of developing at least one bloodstream infection (BSI) episode (largely due to Gram‐positive pathogens) of almost 50% after 30 days at risk in severe COVID‐19 patients. (2) Similarly, Somers et al. reported an increased risk to develop bacterial superinfections, principally represented by Staphylococcus aureus ventilatory associated pneumonia (VAP), in critically ill patients infected with SARS‐CoV‐2 and treated with Tocilizumab.

The Helicobacter cinaedi antigen CAIP participates in atherosclerotic inflammation by promoting the differentiation of macrophages in foam cells

Recent studies have shown that certain speci c microbial infections participate in atherosclerosis by inducing in ammation and immune reactions, but how the pathogens implicated in this pathology trigger the host responses remains unknown. In this study we show that Helicobacter cinaedi (Hc) is a human pathogen linked to atherosclerosis development since at least 27% of sera from atherosclerotic patients speci cally recognize a protein of the Hc proteome, that we named Cinaedi Atherosclerosis In ammatory Protein (CAIP) (n = 71).

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma